IN2013MU03704A - - Google Patents

Info

Publication number
IN2013MU03704A
IN2013MU03704A IN3704MU2013A IN2013MU03704A IN 2013MU03704 A IN2013MU03704 A IN 2013MU03704A IN 3704MU2013 A IN3704MU2013 A IN 3704MU2013A IN 2013MU03704 A IN2013MU03704 A IN 2013MU03704A
Authority
IN
India
Prior art keywords
pharmaceutically acceptable
acceptable derivative
ceftibuten
cefpodoxime
cefixime
Prior art date
Application number
Other languages
English (en)
Inventor
Mahesh Vithalbhai Patel
Sachin Bhagwat
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US15/036,517 priority Critical patent/US20160296502A1/en
Priority to MX2016006788A priority patent/MX2016006788A/es
Priority to BR112016012053A priority patent/BR112016012053A2/pt
Priority to PCT/IB2014/066351 priority patent/WO2015079389A1/fr
Priority to EP14827266.9A priority patent/EP3074014A1/fr
Priority to CN201480064828.1A priority patent/CN105792827B/zh
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Priority to CA2931070A priority patent/CA2931070A1/fr
Priority to JP2016533130A priority patent/JP6525999B2/ja
Priority to IN3704MU2013 priority patent/IN2013MU03704A/en
Priority to KR1020167015290A priority patent/KR20160090311A/ko
Publication of IN2013MU03704A publication Critical patent/IN2013MU03704A/en
Priority to US15/968,174 priority patent/US20180243274A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN3704MU2013 2013-11-26 2014-11-26 IN2013MU03704A (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MX2016006788A MX2016006788A (es) 2013-11-26 2014-11-26 Composiciones antibacterianas.
BR112016012053A BR112016012053A2 (pt) 2013-11-26 2014-11-26 Composições antibacterianas
PCT/IB2014/066351 WO2015079389A1 (fr) 2013-11-26 2014-11-26 Compositions antibactériennes
EP14827266.9A EP3074014A1 (fr) 2013-11-26 2014-11-26 Compositions antibactériennes
CN201480064828.1A CN105792827B (zh) 2013-11-26 2014-11-26 抗菌组合物
US15/036,517 US20160296502A1 (en) 2013-11-26 2014-11-26 Antibacterial compositions
CA2931070A CA2931070A1 (fr) 2013-11-26 2014-11-26 Compositions antibacteriennes
JP2016533130A JP6525999B2 (ja) 2013-11-26 2014-11-26 抗菌性組成物
IN3704MU2013 IN2013MU03704A (fr) 2013-11-26 2014-11-26
KR1020167015290A KR20160090311A (ko) 2013-11-26 2014-11-26 항균성 조성물
US15/968,174 US20180243274A1 (en) 2013-11-26 2018-05-01 Antibacterial compositions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3704MU2013 IN2013MU03704A (fr) 2013-11-26 2014-11-26

Publications (1)

Publication Number Publication Date
IN2013MU03704A true IN2013MU03704A (fr) 2015-07-31

Family

ID=52347362

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3704MU2013 IN2013MU03704A (fr) 2013-11-26 2014-11-26

Country Status (10)

Country Link
US (2) US20160296502A1 (fr)
EP (1) EP3074014A1 (fr)
JP (1) JP6525999B2 (fr)
KR (1) KR20160090311A (fr)
CN (1) CN105792827B (fr)
BR (1) BR112016012053A2 (fr)
CA (1) CA2931070A1 (fr)
IN (1) IN2013MU03704A (fr)
MX (1) MX2016006788A (fr)
WO (1) WO2015079389A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018074985A2 (pt) * 2016-06-17 2019-03-12 Wockhardt Limited composições antibacterianas
SG11201811345TA (en) * 2016-07-14 2019-01-30 Achaogen Inc Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
MX2019010112A (es) * 2017-03-02 2019-10-15 Wockhardt Ltd Compuestos antibacterianos.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8796257B2 (en) * 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
SG10201605368UA (en) * 2012-05-30 2016-08-30 Meiji Seika Pharma Co Ltd NOVEL β-LACTAMASE INHIBITOR AND PROCESS FOR PREPARING THE SAME
WO2014033560A1 (fr) * 2012-08-25 2014-03-06 Wockhardt Limited Dérivés de 1,6-diazabicyclo[3,2,1]octan-7-one et leur utilisation dans le traitement d'infections bactériennes

Also Published As

Publication number Publication date
CA2931070A1 (fr) 2015-06-04
JP2016537386A (ja) 2016-12-01
EP3074014A1 (fr) 2016-10-05
US20160296502A1 (en) 2016-10-13
CN105792827A (zh) 2016-07-20
MX2016006788A (es) 2016-09-07
BR112016012053A2 (pt) 2017-08-08
CN105792827B (zh) 2020-09-08
KR20160090311A (ko) 2016-07-29
US20180243274A1 (en) 2018-08-30
JP6525999B2 (ja) 2019-06-05
WO2015079389A1 (fr) 2015-06-04

Similar Documents

Publication Publication Date Title
EP3582790A4 (fr) Compositions immunogènes très puissantes
PH12016501813B1 (en) 1,3-benzodioxole derivative
MX2020004504A (es) Derivados de fenoximetilo.
EP3389783A4 (fr) Nouveaux composés utilisés comme inhibiteurs de l'indoléamine 2,3-dioxygénase
MX2016011992A (es) Derivados de piperidina-diona.
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
PH12018500061A1 (en) Oxysterols and methods of use thereof
GEP20186933B (en) Substituted dihydroisoquinoline compounds
WO2014144545A3 (fr) Benzoxazoles substitués et leurs procédés d'utilisation
MX2017014035A (es) Formas solidas novedosas.
PH12016501252A1 (en) Novel tetrahydropyridopyrimidine compound or salt thereof
MX2015015562A (es) Dihidropiridinona como inhibidores de monoacilglicerol aciltransferasa 2.
MX2016013431A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
MX363530B (es) Compuesto de benzoxaborol tricíclico, método de preparación y uso del mismo.
MX2018001517A (es) Derivados sustituidos de guanidina.
EP3703692A4 (fr) Nouveaux composés de tétrahydroquinoline substitués utilisés en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido)
EP3694502A4 (fr) Nouveaux composés cyclobutylbenzene substitués utilisés en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido)
EP3389633A4 (fr) Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine
IN2013MU03704A (fr)
MA39877A (fr) Formes solides d'un composé pharmaceutiquement actif
MX2016005539A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
IN2013MU03309A (fr)
IN2014MU00859A (fr)